Obesity race heats up as Arena submits lorcaserin to US FDA
This article was originally published in Scrip
Executive Summary
Arena Pharmaceuticals has filed its lorcaserin with the US FDA, making it the first anti-obesity drug to be filed in a much-watched three horse race. Vivus says it is on track to file its Qnexa (topiramate and phentermine) by the end of the year, and Orexigen plans to file its Contrave (naltrexone sustained-release/bupropion SR) in the first half of 2010.